Martingale Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Martingale Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	+8,406	New	+$1.02M	0.03%	481

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Martingale Asset Management's PVLA Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 8,406 shares worth $1.28M. The stake represents 0.03% of the portfolio and ranks #481 among its holdings.

197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Martingale Asset Management held 8,406 shares of Palvella Therapeutics worth $1.28M as of Q2 2026.
Palvella Therapeutics was a new Martingale Asset Management position in Q2 2026.
Palvella Therapeutics made up 0.03% of Martingale Asset Management's portfolio in Q2 2026, its #481 holding.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.